Innoviva, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
139.4% vs price
Base Case (Median)
171.7% vs price
Bull Case (75th pct.)
477.4% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $150.82 | 619.6% | High (40%) |
| PE Comparable | $91.24 | 335.3% | Medium (25%) |
| Growth Trajectory DCF | $236.86 | 1030.1% | Medium (20%) |
| Graham Number | $40.07 | 91.2% | Medium (40%) |
| EV/EBITDA | $56.95 | 171.7% | Medium (20%) |
| EV/FCF | $55.89 | 166.6% | Medium (20%) |
| Earnings Power Value | $44.45 | 112.1% | Medium (50%) |
Based on 7 out of 8 methods, INVA appears undervalued at the current price of $20.96. The base case fair value of $56.95 implies 171.7% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.